Curis (FRA:CUS1) Institutional Ownership: 7.11% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CUS1 Curis Inc FRA:CUS1
55 GF Score
Price €4.20
GF Value €1.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Curis Institutional Ownership?

Curis FRA:CUS1 -5.52% 55 Institutional Ownership is 7.11% as of Jul. 16, 2026. GuruFocus rates FRA:CUS1 with a GF Score™ of 55/100 and a GF Value™ of €1.29 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Curis's institutional ownership is 7.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Curis's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Curis's Float Percentage Of Total Shares Outstanding is 98.92%.

Curis Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Curis's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Institutional Ownership Chart

Curis Historical Data

The historical data trend for Curis can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 4.96 4.96 4.88 4.81 4.81 5.10 6.00 5.98 6.45 7.11
FRA:CUS1
55GF Score
Curis Inc FRA:CUS1
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 7.11% mean?
Curis (FRA:CUS1) has a Institutional Ownership of 7.11% as of Jul. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Curis and its competitors.
Is Curis' Institutional Ownership too high?
Curis' current Institutional Ownership is 7.11%. Overall, Curis has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curis' Institutional Ownership compare to CALC and ICU?
Curis' Institutional Ownership of 7.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Curis and its competitors. Curis's current Institutional Ownership is 7.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis stock overvalued right now?
Based on GuruFocus' analysis, Curis (FRA:CUS1) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.29, compared to a current price of €4.20 — trading 225.2% above its estimated fair value. The current Institutional Ownership is 7.11%. Curis' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Curis (FRA:CUS1), the current Institutional Ownership is 7.11% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Curis (FRA:CUS1) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be overvalued. The current stock price of €4.20 is trading 225.2% above its estimated GF Value™ of €1.29. GuruFocus considers Curis to be Significantly Overvalued.

Key valuation signals for FRA:CUS1:

  • Institutional Ownership: 7.11%
  • GF Value™: €1.29 vs. price of €4.20 (225.2% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
55GF Score

Get the complete analysis for FRA:CUS1

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.20
Price
€1.29
GF Value